Report cover image

Global Transdermal Drug Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 209 Pages
SKU # APRC20280461

Description

Summary

According to APO Research, the global Transdermal Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Transdermal Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Transdermal Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Transdermal Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Transdermal Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Transdermal Drug market include Johnson & Johnson, Novartis, Mylan, GSK, Beijing Tide Pharmaceutical, Bayer, UCB Pharma, Teva Pharmaceutical and Nitto Denko, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Transdermal Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Transdermal Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Transdermal Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Transdermal Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Transdermal Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Transdermal Drug sales, projected growth trends, production technology, application and end-user industry.

Transdermal Drug Segment by Company

Johnson & Johnson
Novartis
Mylan
GSK
Beijing Tide Pharmaceutical
Bayer
UCB Pharma
Teva Pharmaceutical
Nitto Denko
Mundipharma
Luye Pharma Group
IBSA Group
Hisamitsu Pharmaceutical
Grünenthal
Dr Reddy’s Laboratories
Chattem
Transdermal Drug Segment by Type

Methyl Salicylate-based Patch
Diclofenac Patch
Nicotine Transdermal Patch
Lidocaine Patch
Rivastigmine Transdermal Patch
Fentanyl Transdermal Patch
Others
Transdermal Drug Segment by Application

Rx Channel
OTC Channel
Transdermal Drug Segment by Region

North America

United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Transdermal Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Transdermal Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Transdermal Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Transdermal Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transdermal Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Transdermal Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transdermal Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Transdermal Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Transdermal Drug industry.
Chapter 3: Detailed analysis of Transdermal Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Transdermal Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Transdermal Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

209 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Transdermal Drug Sales Value (2020-2031)
1.2.2 Global Transdermal Drug Sales Volume (2020-2031)
1.2.3 Global Transdermal Drug Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Transdermal Drug Market Dynamics
2.1 Transdermal Drug Industry Trends
2.2 Transdermal Drug Industry Drivers
2.3 Transdermal Drug Industry Opportunities and Challenges
2.4 Transdermal Drug Industry Restraints
3 Transdermal Drug Market by Company
3.1 Global Transdermal Drug Company Revenue Ranking in 2024
3.2 Global Transdermal Drug Revenue by Company (2020-2025)
3.3 Global Transdermal Drug Sales Volume by Company (2020-2025)
3.4 Global Transdermal Drug Average Price by Company (2020-2025)
3.5 Global Transdermal Drug Company Ranking (2023-2025)
3.6 Global Transdermal Drug Company Manufacturing Base and Headquarters
3.7 Global Transdermal Drug Company Product Type and Application
3.8 Global Transdermal Drug Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Transdermal Drug Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Transdermal Drug Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Transdermal Drug Market by Type
4.1 Transdermal Drug Type Introduction
4.1.1 Methyl Salicylate-based Patch
4.1.2 Diclofenac Patch
4.1.3 Nicotine Transdermal Patch
4.1.4 Lidocaine Patch
4.1.5 Rivastigmine Transdermal Patch
4.1.6 Fentanyl Transdermal Patch
4.1.7 Others
4.2 Global Transdermal Drug Sales Volume by Type
4.2.1 Global Transdermal Drug Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Transdermal Drug Sales Volume by Type (2020-2031)
4.2.3 Global Transdermal Drug Sales Volume Share by Type (2020-2031)
4.3 Global Transdermal Drug Sales Value by Type
4.3.1 Global Transdermal Drug Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Transdermal Drug Sales Value by Type (2020-2031)
4.3.3 Global Transdermal Drug Sales Value Share by Type (2020-2031)
5 Transdermal Drug Market by Application
5.1 Transdermal Drug Application Introduction
5.1.1 Rx Channel
5.1.2 OTC Channel
5.2 Global Transdermal Drug Sales Volume by Application
5.2.1 Global Transdermal Drug Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Transdermal Drug Sales Volume by Application (2020-2031)
5.2.3 Global Transdermal Drug Sales Volume Share by Application (2020-2031)
5.3 Global Transdermal Drug Sales Value by Application
5.3.1 Global Transdermal Drug Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Transdermal Drug Sales Value by Application (2020-2031)
5.3.3 Global Transdermal Drug Sales Value Share by Application (2020-2031)
6 Transdermal Drug Regional Sales and Value Analysis
6.1 Global Transdermal Drug Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Transdermal Drug Sales by Region (2020-2031)
6.2.1 Global Transdermal Drug Sales by Region: 2020-2025
6.2.2 Global Transdermal Drug Sales by Region (2026-2031)
6.3 Global Transdermal Drug Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Transdermal Drug Sales Value by Region (2020-2031)
6.4.1 Global Transdermal Drug Sales Value by Region: 2020-2025
6.4.2 Global Transdermal Drug Sales Value by Region (2026-2031)
6.5 Global Transdermal Drug Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Transdermal Drug Sales Value (2020-2031)
6.6.2 North America Transdermal Drug Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Transdermal Drug Sales Value (2020-2031)
6.7.2 Europe Transdermal Drug Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Transdermal Drug Sales Value (2020-2031)
6.8.2 Asia-Pacific Transdermal Drug Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Transdermal Drug Sales Value (2020-2031)
6.9.2 South America Transdermal Drug Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Transdermal Drug Sales Value (2020-2031)
6.10.2 Middle East & Africa Transdermal Drug Sales Value Share by Country, 2024 VS 2031
7 Transdermal Drug Country-level Sales and Value Analysis
7.1 Global Transdermal Drug Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Transdermal Drug Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Transdermal Drug Sales by Country (2020-2031)
7.3.1 Global Transdermal Drug Sales by Country (2020-2025)
7.3.2 Global Transdermal Drug Sales by Country (2026-2031)
7.4 Global Transdermal Drug Sales Value by Country (2020-2031)
7.4.1 Global Transdermal Drug Sales Value by Country (2020-2025)
7.4.2 Global Transdermal Drug Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Transdermal Drug Sales Value Growth Rate (2020-2031)
7.5.2 USA Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Transdermal Drug Sales Value Growth Rate (2020-2031)
7.6.2 Canada Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Transdermal Drug Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Transdermal Drug Sales Value Growth Rate (2020-2031)
7.8.2 Germany Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Transdermal Drug Sales Value Growth Rate (2020-2031)
7.9.2 France Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.9.3 France Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Transdermal Drug Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Transdermal Drug Sales Value Growth Rate (2020-2031)
7.11.2 Italy Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Transdermal Drug Sales Value Growth Rate (2020-2031)
7.12.2 Spain Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Transdermal Drug Sales Value Growth Rate (2020-2031)
7.13.2 Russia Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Transdermal Drug Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Transdermal Drug Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Transdermal Drug Sales Value Growth Rate (2020-2031)
7.16.2 China Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.16.3 China Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Transdermal Drug Sales Value Growth Rate (2020-2031)
7.17.2 Japan Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Transdermal Drug Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Transdermal Drug Sales Value Growth Rate (2020-2031)
7.19.2 India Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.19.3 India Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Transdermal Drug Sales Value Growth Rate (2020-2031)
7.20.2 Australia Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Transdermal Drug Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Transdermal Drug Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Transdermal Drug Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Transdermal Drug Sales Value Growth Rate (2020-2031)
7.24.2 Chile Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Transdermal Drug Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Transdermal Drug Sales Value Growth Rate (2020-2031)
7.26.2 Peru Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Transdermal Drug Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Transdermal Drug Sales Value Growth Rate (2020-2031)
7.28.2 Israel Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Transdermal Drug Sales Value Growth Rate (2020-2031)
7.29.2 UAE Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Transdermal Drug Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Transdermal Drug Sales Value Growth Rate (2020-2031)
7.31.2 Iran Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Transdermal Drug Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Transdermal Drug Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Transdermal Drug Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Transdermal Drug Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Johnson & Johnson
8.1.1 Johnson & Johnson Comapny Information
8.1.2 Johnson & Johnson Business Overview
8.1.3 Johnson & Johnson Transdermal Drug Sales, Value and Gross Margin (2020-2025)
8.1.4 Johnson & Johnson Transdermal Drug Product Portfolio
8.1.5 Johnson & Johnson Recent Developments
8.2 Novartis
8.2.1 Novartis Comapny Information
8.2.2 Novartis Business Overview
8.2.3 Novartis Transdermal Drug Sales, Value and Gross Margin (2020-2025)
8.2.4 Novartis Transdermal Drug Product Portfolio
8.2.5 Novartis Recent Developments
8.3 Mylan
8.3.1 Mylan Comapny Information
8.3.2 Mylan Business Overview
8.3.3 Mylan Transdermal Drug Sales, Value and Gross Margin (2020-2025)
8.3.4 Mylan Transdermal Drug Product Portfolio
8.3.5 Mylan Recent Developments
8.4 GSK
8.4.1 GSK Comapny Information
8.4.2 GSK Business Overview
8.4.3 GSK Transdermal Drug Sales, Value and Gross Margin (2020-2025)
8.4.4 GSK Transdermal Drug Product Portfolio
8.4.5 GSK Recent Developments
8.5 Beijing Tide Pharmaceutical
8.5.1 Beijing Tide Pharmaceutical Comapny Information
8.5.2 Beijing Tide Pharmaceutical Business Overview
8.5.3 Beijing Tide Pharmaceutical Transdermal Drug Sales, Value and Gross Margin (2020-2025)
8.5.4 Beijing Tide Pharmaceutical Transdermal Drug Product Portfolio
8.5.5 Beijing Tide Pharmaceutical Recent Developments
8.6 Bayer
8.6.1 Bayer Comapny Information
8.6.2 Bayer Business Overview
8.6.3 Bayer Transdermal Drug Sales, Value and Gross Margin (2020-2025)
8.6.4 Bayer Transdermal Drug Product Portfolio
8.6.5 Bayer Recent Developments
8.7 UCB Pharma
8.7.1 UCB Pharma Comapny Information
8.7.2 UCB Pharma Business Overview
8.7.3 UCB Pharma Transdermal Drug Sales, Value and Gross Margin (2020-2025)
8.7.4 UCB Pharma Transdermal Drug Product Portfolio
8.7.5 UCB Pharma Recent Developments
8.8 Teva Pharmaceutical
8.8.1 Teva Pharmaceutical Comapny Information
8.8.2 Teva Pharmaceutical Business Overview
8.8.3 Teva Pharmaceutical Transdermal Drug Sales, Value and Gross Margin (2020-2025)
8.8.4 Teva Pharmaceutical Transdermal Drug Product Portfolio
8.8.5 Teva Pharmaceutical Recent Developments
8.9 Nitto Denko
8.9.1 Nitto Denko Comapny Information
8.9.2 Nitto Denko Business Overview
8.9.3 Nitto Denko Transdermal Drug Sales, Value and Gross Margin (2020-2025)
8.9.4 Nitto Denko Transdermal Drug Product Portfolio
8.9.5 Nitto Denko Recent Developments
8.10 Mundipharma
8.10.1 Mundipharma Comapny Information
8.10.2 Mundipharma Business Overview
8.10.3 Mundipharma Transdermal Drug Sales, Value and Gross Margin (2020-2025)
8.10.4 Mundipharma Transdermal Drug Product Portfolio
8.10.5 Mundipharma Recent Developments
8.11 Luye Pharma Group
8.11.1 Luye Pharma Group Comapny Information
8.11.2 Luye Pharma Group Business Overview
8.11.3 Luye Pharma Group Transdermal Drug Sales, Value and Gross Margin (2020-2025)
8.11.4 Luye Pharma Group Transdermal Drug Product Portfolio
8.11.5 Luye Pharma Group Recent Developments
8.12 IBSA Group
8.12.1 IBSA Group Comapny Information
8.12.2 IBSA Group Business Overview
8.12.3 IBSA Group Transdermal Drug Sales, Value and Gross Margin (2020-2025)
8.12.4 IBSA Group Transdermal Drug Product Portfolio
8.12.5 IBSA Group Recent Developments
8.13 Hisamitsu Pharmaceutical
8.13.1 Hisamitsu Pharmaceutical Comapny Information
8.13.2 Hisamitsu Pharmaceutical Business Overview
8.13.3 Hisamitsu Pharmaceutical Transdermal Drug Sales, Value and Gross Margin (2020-2025)
8.13.4 Hisamitsu Pharmaceutical Transdermal Drug Product Portfolio
8.13.5 Hisamitsu Pharmaceutical Recent Developments
8.14 Grünenthal
8.14.1 Grünenthal Comapny Information
8.14.2 Grünenthal Business Overview
8.14.3 Grünenthal Transdermal Drug Sales, Value and Gross Margin (2020-2025)
8.14.4 Grünenthal Transdermal Drug Product Portfolio
8.14.5 Grünenthal Recent Developments
8.15 Dr Reddy’s Laboratories
8.15.1 Dr Reddy’s Laboratories Comapny Information
8.15.2 Dr Reddy’s Laboratories Business Overview
8.15.3 Dr Reddy’s Laboratories Transdermal Drug Sales, Value and Gross Margin (2020-2025)
8.15.4 Dr Reddy’s Laboratories Transdermal Drug Product Portfolio
8.15.5 Dr Reddy’s Laboratories Recent Developments
8.16 Chattem
8.16.1 Chattem Comapny Information
8.16.2 Chattem Business Overview
8.16.3 Chattem Transdermal Drug Sales, Value and Gross Margin (2020-2025)
8.16.4 Chattem Transdermal Drug Product Portfolio
8.16.5 Chattem Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Transdermal Drug Value Chain Analysis
9.1.1 Transdermal Drug Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Transdermal Drug Sales Mode & Process
9.2 Transdermal Drug Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Transdermal Drug Distributors
9.2.3 Transdermal Drug Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.